As a staff writer for Forbes Advisor, SMB, Kristy helps small business owners find the tools they need to keep their businesses running. She uses the experience of managing her own writing and editing ...

本仓库用来存放 B 站课程 《现代 C++ 模板教程 2024》的教案、代码，和作业。 任何组织和个人遵守 CC BY-NC-ND 4.0 ...

A and South Walton dog owners can access board and train, in-home lessons, and behavior programs across Santa Rosa Beach, Destin, and nearby communities. SANTA ROSA, FL, UNITED STATES, January 5, 2026 ...

This month, I’ll share some of the free software I use to understand how TV signals make it from the transmitter to the ...

This blog will explore the importance, features, benefits, challenges, and future trends associated with pharmacy delivery software. Whether you’re a pharmacy owner, healthcare provider ...

The AI Software Development Kit, or AI SDK for short, is a set of Python libraries. These libraries provide building blocks for automating the creation, packaging, and testing of inference pipelines ...

BioMarin Pharmaceutical has entered into a definitive agreement to acquire rare disease biotech, Amicus Therapeutics for $4.8bn. Image credit: T. Schneider via ShutterStock.com. BioMarin ...

BioMarin Pharmaceutical (BMRN) has agreed to acquire rare disease drug developer Amicus Therapeutics (FOLD) in an all-cash transaction worth nearly $4.8B, the companies announced on Friday. The deal, ...

Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases. The drugmaker ...

SAN RAFAEL, Calif., and PRINCETON, N.J., Dec. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into ...

BioMarin’s $4.8 billion all-cash acquisition of Amicus Therapeutics significantly expands its rare disease portfolio with established Fabry and Pompe franchises, adds late-stage pipeline upside, and ...

BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in ...